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al. publication noted that studies have eluded to the

METHOD FOR INHIBITING ANGIOGENESIS

WITH AURINTRICARBOXYLIC ACID, ITS
ANALOGUES OR SALTS

TECHNICAL FIELD
This invention relates to the discovery that aurin

tricarboxylic acid has potent anti-angiogenic properties
and activity and thus may be used for new therapeutic

approaches for diseases of neovascularization including
the treatment of solid tumors, diabetic retinopathy and
arthritis, among others.

BACKGROUND ART

variable activity of commercial ATA preparations and
that the commonly accepted structure of ATA might
not be the true inhibitor of protein-nucleic acid interac
tions.

Mellon, W. S “Inhibitory Action of Aurintricarboxy
lic Acid and Rifamycin AF/0l3 at the Polynucleotide
Domain of 1,25-Dihydroxyvitamin D3-Receptor Com
plexes”, Biochemical Pharmacology, Volume 33, Num
ber 7, (1984) pp. 1047-1057, discloses that the binding of

l,25~dihydroxyvitamin Dg-receptor complexes from
chicken intestine to DNA-cellulose and isolated intesti
nal nuclei is inhibited in a dose-dependent manner by

ATA and rifamycin AF/0l3, which are known poly

US. Pat. No. 4,007,270 to Bernstein et al. discloses

merase inhibitors. Mellon concluded that the observed

that aurintricarboxylic acid (ATA) and certain of its

inhibition was caused by ATA directly inhibiting the
receptor. Mellon suggests that the receptor and polyme
rases have corresponding properties, but states that the

derivatives and salts are useful as complement inhibitors

which play an important role as mediators in immune,

allergic, immunochemical and immunopathological

question remains whether this is an insubstantial similar
reactions. The patent discloses a method of inhibiting 0 ity or it is structurally relevant to hormone action.
the complement system in blood serum subjecting the
Moudgil, V. K. et al. “Modulation of DNA Binding
serum to aurintricarboxylic acid or its derivatives or

salts and that ATA has anti-in?ammatory properties.
US. Pat. No. 4,880,788 to Moake et al. discloses a

method for preventing and treating thrombosis. Moake
et al. suggest that aurintricarboxylic acid may prevent
yon Willebrand Factor mediated aggregation or agglu

tination of platelets and thereby prevents for formation
of thromboemboli.
Cushman, M. et al. “Preparation and Anti-HIV Ac
tivities of Aurintricarboxylic Acid Fractions and Ana
logues: Direct Correlation of Antiviral Potency with

Molecular Weight”, J. Med. Chem, Volume 34, (1991)
pp. 329-337, disclose that aurintricarboxylic acid
(ATA) binds to small gpl20 in the absence of CD4
binding and is sufficient for anti-HIV activity.
Cushman, M. et al., “Synthesis and Anti-HIV Activi
ties of Low Molecular Weight Aurintricarboxylic Acid
Fragments and Related Compounds”, J. Med. Chem.,
Volume 34, (1991) pp. 337-342, disclose derivatives of
aurintricarboxylic acid and their ability to afford pro
tection against the cytopathogenicity of HIV-2 in MT-4
cell and HIV-1 in CEM cells. Two derivatives of ATA

of Glucocorticoid Receptor by Aurintricarboxylic
Acid”, J. Steroid Bi0chem., Volume 23, Number 2,
(1985) pp. 125-132, disclose that ATA is an inhibitor of
the DNA-binding of rat liver glucocorticoid-receptor
complex. They found that treatment with ATA did not
appear to alter the steroid binding properties of the
receptor or accelerate dissociation of the complex.
Moudgil et al. concluded that ATA does not inhibit the
process of receptor activation and that it may act via
interaction with the DNA-binding sites at the glucocor
ticoid-receptor. They suggest that the interaction may
result in an alteration in the conformation of the acti

vated receptor to a form unfavorable for optimum
DNA-binding. They suggest that the skeletal structure
of triphenylmethane, rather than the side chains, is the
site of inhibitory action of ATA. Moudgil et al. reserve

that the evidence presented in their study only indi
40 rectly argues in favor of an interaction between ATA

and the glucocorticoid-receptors and that further stud
ies are required to con?rm the interaction.
Nakane, H. et al. “Differential Inhibition of various

Deoxyribonucleic Acid Polymerases by Evans Blue
were found to inhibit syncytium formation. In contrast
to ATA itself, two of the derivatives of ATA were 45 and Aurintri-carboxylic Acid”, Eur. J. Biochem, Vol
ume 177, (1988) pp. 91-96, disclose that both Evans blue
inactive when tested for prevention of the binding of
and ATA exhibited inhibitor effects on the in vitro
the OKT4A monoclonal antibody to the CD4 receptor
activity of all DNA polymerases, including human
and also for the inhibition of HIV-1 reverse transcrip
DNA polymerases, a, B, 7-, DNA primase, calf-thymus
tase. It was concluded by Cushman et al. that these
derivatives appear to act by a mechanism that is distinct 50 terminal deoxynucleotidyltransferase, RLV reverse
transcriptase, E. coli DNA polymerase I, and RNA
from that of polymeric ATA. Cushman et al. do not
polymerase.
disclose a method of use of aurintricarboxylic acid or its
Skidmore, A. F. et al. “Characterization and Use of
analogues or derivatives as an anti-angiogenic agent.
the Potent Ribonuclease Inhibitor Aurintricarboxylic
Gonzalez, R. G. et al. “Fractionation and Structural
Elucidation of the Active Components of Aurintricar 55 Acid for the Isolation of RNA from Animal Tissues”,
Biochem. J., Volume 263, (1989) pp. 73-80, disclose
boxylic Acid, a Potent Inhibitor of Protein Nucleic
studies of ATA which yield that it is very useful as an
Acid Interactions”. Biochimica et Biophysica Acta, Vol
RNAase inhibitor.
ume 562, (1979) pp. 534-545, disclose that the triphenyl
methane dye, aurintricarboxylic acid, is a potent inhibi
tor of protein-nucleic acid interactions. Gonzalez et al.
noted that the degree of inhibitory activity of the aurin

Schols, D. et al., “Speci?c Interaction of Aurintricar
boxylic Acid with the Human Immunode?ciency Vi
rus/CD4 Cell Receptor”, Proc. Natl. Acad. Sci. USA,
Volume 86, (May 1989) pp. 3322-3326, disclose that

tricarboxylic acid preparation depends on the degree of
ATA is a compound that affects a rapid and selective
polymerization of the aurintricarboxylic acid polymer.
modulation of CD-4 receptor expression on T4'*' cells
The experimentation examined the ability of three frac
tions of ATA to inhibit DNA-poly L-lysine complex 65 without affecting the expression of other cell-surface
formation. Two biologically relevant assays were used
based on the binding of polyribouridylic acid to ribo

markers. Schols et al. suggest that the exact mechanism
by which ATA blocks a CD-4 receptor remains un

somal S1 and to E. coli 70-S ribosomes. The Gonzalez et

known but the anionic character of ATA suggests that

3
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ATA should be able to bind to lysine and/or arginine
residues. Strony, J. et al. “Aurintricarboxylic Acid in a

heparin production lots and thus in glycosaminoglycans

Canine Model of Coronary Artery Thrombosis”, Circu
lation, Volume 81, Number 3, (March 1990) pp.
1106-1114, disclose that ATA is unique in its inhibition
of glycoprotein Ib-mediated platelet adhesion and sub
sequent aggregation. Strony et al. suggest that platelet

Folkman, J. et al. “Angiogenesis Inhibition and
Tumor Regression Caused by Heparin or a Heparin

of different chemical structure.

Fragment in the Presence of Cortisone”, Science, Vol
ume 221, (Aug. 19, 1983) pp. 719-725, disclose the in

hibitory effect of heparin-cortisone.

Allain et al., “Mise en evidence de l’action anti
glycoprotein Ib-von Willebrand factor interactions are
in?ammatoire de l’alumninon ou acide aurine tribox
important during coronary occlusion and that ATA can
ylique”, C. R. Seances Soc. Biol. Fil, Volume 174,
inhibit coronary thrombosis associated with coronary
(1980) pp. 68-73, disclose that aurintricarboxylic acid
constriction. Strony et al. do not state that the inhibition
reduces Freund adjuvant-induced arthritis and cara
of coronary occlusion is due to anti-angiogenic proper
geen-induced oedemas in the paws of rats. Allain et al.
ties of ATA.
do not disclose that aurintricarboxylic acid has anti
Benezra, M. et al. “Reversal of Basic Fibroblast
Growth Factor-mediated Autocrine Cell Transforma 15 angiogenic properties but disclose the use of aurintricar
boxylic acid as an anti-in?ammatory agent for the treat
tion by Aromatic Anionic Compounds”, Cancer Re
ment of arthritis.

search, Volume 52, (Oct. 15, 1992) pp. 5656-5662, dis
close that ATA binds to basic ?broblast growth factor.

DISCLOSURE OF THE INVENTION

Benezra et al. disclose that a common feature of com

pounds such as ATA and other dyes is their ability to 20

mimic many of the biological effects of heparin such as
anti-coagulation, release of ECM-bound bFGF, inhibi

tion of heparanase activity and interaction with lipopro
tein lipase. The study suggests that the effect of ATA
may not be due to the actual interaction with bFGF,

It is an object of the present invention to provide a

method for use of aurintricarboxylic acid, its analogues,
salts and derivatives as anti-angiogenic agents or inhibi

tors of angiogenesis.
It is another object of the present invention to pro
25 vide a method for the treatment of diseases which are

anglogenesis-dependent such as the treatment of solid

suggesting that ATA may function by blocking the

tumors, diabetic retinopathy, arthritis, for example.

participation of bFGF in an intracellular autocrine

It is another object of the present invention to pro
vide a pharmaceutical composition for the treatment of
Kan, M. et al. “An Essential Heparin-binding Do 30 diseases which are angiogenesis-dependent diseases.
main in the Fibroblast Growth Factor Receptor Ki
A further object of the present invention provides a

pathway.

nase”, Science, Volume 259, (Mar. 26, 1993) pp.
1918-1921, disclose that heparin or heparin-like heparan

method of inhibiting anglogenesis using a compound
which is not mitogenic to cells of an animal.

sulfate proteoglycans are necessary for activity of the

heparin-binding ?broblast growth factor family. Hepa
rin interacts independently of the FGF ligand with a
speci?c sequence (K18K) in one of the immunoglobu
lin-like loops in the extracellular domain of the FGF

receptor tyrosine kinase transrnembrane glycoprotein.

35

BRIEF DESCRIPTION OF THE DRAWING
FIG. 1 shows the percentage of inhibition of anglo
genesis due to increasing amounts of aurintn'carboxylic
acid (ATA) and aurin, with and without heparin.

Kan et al. found that a synthetic peptide corresponding

DESCRIPTION OF THE INVENTION

to the K18K inhibited heparin and heparin dependent
FGF binding to the receptor.
Bouck, N. “Tumor Angiogenesis: The Role of Onco
genes and Tumor Suppressor Genes”, Cancer Cells,
Volume 2, Number 6, (June 1990) pp. 179-185, discloses
that the progressive growth of solid tumors is strictly

Anglogenesis is the formation of blood and lymph
vessels. Angiogenesis dependent diseases include, but

dependent on their ability to attract new blood vessels

that will supply them with oxygen and essential nutri

are not limited to, tumor growth and metastasis, dia

betic retinopathy, neovascular glaucoma and rheuma
45 toid arthritis.

Thus, there is a need for experimentation and discov

ery of compounds, pharmaceutical compositions and
methods for the inhibition of angiogenesis.

ents. Angiogenesis has been shown to precede or ac

It has now been discovered that the aurintricarboxy
company malignancy. The focus of Bouck’s study was 50 lic acid compounds and compositions of this invention
to con?rm that suppressor gene loss can in?uence angi
are useful in the inhibition of angiogenesis and thus in
ogenesis. Bouck conjectures that molecules produced
the treatment of diseases which are anglogenesis
by normal cells that block angiogenesis may be helpful
dependent.
in combating tumor growth and the molecules pro
Standard angiogenesis assays are well known in the
duced by tumor cells that promote angiogenesis may be 55 art. These assays include proliferation and migration

useful targets for anti-tumor drugs.
Gagliardi, A. et a1. “Inhibition of Angiogenesis by

and an in vivo angiogenesis assay on chicken chorioal

Suramin”, Cancer Research, Volume 52, (Sep. 15, 1992)

lantoic membranes (CAM) (see Auerbach, Dev. Biol.

studies using various cell lines, collagenase inhibition

pp. 5073-5075, disclose the ability of suramin to inhibit
(1974) 41:391; and Crum, Science, Volume 230, (1985) p.
anglogenesis in chick chorioallantoic membrane. Ga 60 1375).
gliardi et al. disclose that suramin alone inhibited anglo
The chorioallantoic membrane of the chick embryo is
genesis, and potentiated the activity of angiostatic ste
often used as a semi-quantitative bioassay of angiogenic
roids. Weisz, P. B. et al., “Anglogenesis and Heparin
activity. The assay is quick and inexpensive and permits
Mimics”, Anglogenesis: Key Princ1ples—Science—Tech
continuous, serial observations of changes in blood
nology-Medicine, (eds. R. Steiner, P. B. Weisz & R. 65 vessel growth. The rapid vascular growth of the CAM
Langer), (1992) pp. 107-117, disclose that glycosami
makes it an ideal model for observing modulation of
noglycans, such as heparin, can modulate angiogenesis
angiogenesis, since sustained release implants contain
and that this modulation varies greatly among varying
ing speci?c test substances can be placed on the grow

5
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ing capillary network of the CAM (see Woltering et al.

and Analogues: Direct Correlation of Antiviral Po

1991. “Somatostatin analogues Inhibit Angiogenesis in

tency with Molecular Weight”, J. Med. Chem., Volume
34, (1991) pp. 329-337; Cushman, M. et al. “Synthesis
and Anti-HIV Activities of Low Molecular Weight
Aurintricarboxylic Acid Fragments and Related Com
pounds”, J. Med. Chem., Volume 34, (1991) pp.

the Chick Chorioallantoic Membrane”, Journal of Sur
gical Research, 50: 245-251; and Oikawa et al. 1989.
Cancer Letters, 48:157-162). The CAM assay is prefer

entially employed for searching for anti~angiogenic
substances. The CAM model has been used to assay
tumor related angiogenesis.
It is widely accepted that human and animal tumors

337-342).
Aurintricarboxylic acid is generally known to have
the formula as set forth below:

can induce endothelial cell mitosis and anglogenesis,

resulting in extensive neovascularization. Thus, angio
genic activity is critical for tumorimplantation and

3

subsequent growth. It has been shown that in the ab

COOH

sence of neovascularization that the size of tumor grafts
becomes limited. It is also known that neovasculariza 15

tion is essential for tumor growth, development, and

metastasis; furthermore, when angiogenesis is absent,

HO

C

tumors tend to remain dormant (see Woltering et al.,

supra). Therefore, angiogenic activity has been directly
correlated with tumor growth.

20

COOl-I

A variety of non-neoplastic diseases, previously

COOH

thought to be unrelated, can be considered “angiogenic
diseases” because they are dominated by the pathologi
cal growth of capillary blood vessels. These diseases

include diabetic retinopathy, arthritis, hemangiomas,
psoriasis, and ocular neovascularization, for example.

OH

25

There seems to belittle or no biochemical difference

The heterogeneous mixture of ATA has been shown
to inhibit protein nucleic acid interactions (Gonzalez, R.
G. et al. “Fractionation and Structural Elucidation of

the Active Components of Aurintricarboxylic Acid, a
Potent Inhibitor of Protein Nucleic Acid Interactions”,
Biochimica et Biophysica Acta, Volume 562, (1979) pp.

between angiogenic peptides expressed by tumors and
those expressed by normal tissues. Nor are there any
morphological differences between the new capillaries

that respond to a malignancy and the capillary growth
that occurs during physiological neovascularization
(see Folkman et al. 1987. “Angiogenic Factors”, Sci
ence, 235: 442-447).
As there is no qualitative difference between the

clear uptake and the nuclear binding levels (Mellon, W.
S., “Inhibitory Action of Aurintricarboxylic Acid and
Rifamycin AF/013 at the Polynucleotide Domain of

angiogenic capabilities of nonmalignant and malignant

chemical Pharmacolog, Volume 33, Number 7, (1984)

diseases, results from normal and malignant vasculariza

pp. 1047-1057; Moudgil, V. K. et al., “Modulation of

tion assays can be easily compared, and progress can be
made in either area independently of the system of in

DNA Binding of Glucocorticoid Receptor by Aurin
tricarboxylic Acid”, J. Steroid Biochem., Volume 23,
Number 2, (1985) pp. 125-132); to inhibit DNA poly

534-545); to interact with steroid receptors at the nu

1,25-Dihydroxyvitamin D3-Receptor Complexes”, Bio

vestigation used (see Paweletz et al. 1989. “Tumor 40
related Angiogenesis”, Critical Reviews in Oncology/
merase (Nakane, H. et al. “Differential Inhibition of
Hematology, Volume 9, Issue 3, p. 197-198; and
various Deoxyribonucleic Acid Polymerases by Evans
Takigawa et al. 1990. “Tumor Angiogenesis and Poly
Blue and Aurintri-carboxylic Acid”, Eur. J. Biochem.,
amines: a-Di?uoromethylornithine, and Irreversible
Volume 177, (1988) pp. 91-96); and to act as a RNAase
Inhibitor of Ornithine Decarboxylase, Inhibits B16 45 inhibitor (Skidmore, A. F. et al. “Characterization and
Melanoma-Induced Angiogenesis in Ovo and the Pro~
Use of the Potent Ribonuclease Inhibitor Aurintricar
liferation of Vascular Endothelial Cells in vitro”, Can
boxylic acid for the Isolation of RNA from Animal
cer Research, 50: 4131-4138).
Tissues”, Biochem. J., Volume 263, (1989) pp. 73-80).
In addition, Glaser et al. have found that cultured
ATA is a nonsulfated negatively-charged aromatic
human retinal pigment epithelial cells release a sub 50
mixture of polymers that competes with heparin sulfate
stance which, when applied to the CAM, causes regres
for binding to bFGF. ATA has been shown to reverse
sion of new blood vessels and also inhibits the prolifera
the transformed phenotype of sp bFGF transformed
tion of bovine endothelial cells in vitro. Thus, the CAM
cells
(cells transfected with a chimeric signal peptide
assay is an acceptable assay for diabetic retinopathy

(Glaser et al., 1983. “Retinal Pigment Epithelial Cells
release inhibitors of neovacularization”, Ophthalmology,
94: p. 780).
Therefore, it is readily understood by one of ordinary
skill in the art that an in vivo CAM assay showing the

55

FGF) in terms of cell proliferation rate, morphological
appearance and adhesive properties (Benezra, M. et al.
“Reversal of Basic Fibroblast Growth Factor-mediated
Autocrine Cell Transformation by Aromatic Anionic

Compounds”, Cancer Research, Volume 52, (Oct. 15,

anti-angiogenic properties of ATA can readily be corre 60 1992) pp. 5656-5662). The capacity of ATA to interfere
with the bFGF autocrine loop suggests important ther
lated to human treatments of angiogenesis-dependent
apeutic potential in neoplastic diseases.
diseases, such as tumor growth, diabetic retinopathy
ATA is also a selective marker molecule for the im
and arthritis.
munode?ciency virus/CD4 receptor (Schols, D. et al.
Aurintricarboxylic acid (ATA) is a heterogeneous
mixture of polymers that forms when salicylic acid is 65 “Speci?c Interaction of Aurintricarboxylic Acid with
the Human Immunode?ciency Virus/CD4 Cell Recep
treated with formaldehyde, sulfuric acid and sodium
tor”, Proc. Natl. Acad. Sci. USA, Volume 86, (May 1989)
nitrite (see Cushman, M. et al. “Preparation and Anti
HIV Activities of Aurintricarboxylic Acid Fractions
pp. 3322-3326).

7
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It inhibits platelet dependent thrombus formation

8

rin or a Heparin Fragment in the Presence of Corti

(Strony, J. et a1. “Aurintricarboxylic Acid in a Canine

sone”, Science, Volume 221, (Aug. 19, 1983) pp.
719-725) showed that heparin and heparin fragments
without anticoagulant activity inhibited angiogenesis in
the presence of cortisol, l7a-hydroxyprogesteroneand

Model of Coronary Artery Thrombosis”, Circulation,
Volume 81, Number 3, (March 1990) pp. 1106-1114),
and reverts basic ?broblast growth factor (bFGF) me
diated autocrine cell transformation. Recent studies
suggest that the interaction of bFGF with cell surface

tetrahydrocortisol.
Experimentation was performed to determine the

heparin sulfate is required for subsequent binding to
high af?nity cell surface receptors and signal transduc

ability of aurintricarboxylic acid, its salts, derivatives

tion by Aromatic Anionic Compounds”, Cancer Re

dependent inhibition of angiogenesis by ATA. In addi
tion, the interaction of ATA with heparin and angio

and analogues to inhibit anglogenesis in the chick cho
tion (Benezra, M. et al. “Reversal of Basic Fibroblast 10 rioallantoic membrane.
Growth Factor-mediated Autocrine Cell Transforma
The example set forth below demonstrates the dose

search, Volume 52, (Oct. 15, 1992) pp. 5656-5662).
Members of the FGF family are characterized by

their high af?nity for glycosaminoglycan and heparin,
and their high mitogenicity for mesoderm and neuroec
toderm derived cells. Furthermore, they are among the
most potent inducers of neovascularization (see Kan, M.
et al., “An Essential Heparin-binding Domain in the

static steroids is described.
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EXAMPLE 1

Materials and Methods
Aurintricarboxylic acid trisodium salt and aurin were

obtained from Aldrich Chemical Company, Milwau
kee, Wis. Procedures for the synthesis of aurintricar
boxylic acid are reported (see Heisig, G. B. and Lauer,
W. M. Org. Syn., Volume 9, (1928) p. 54-55.) Aurin
basic Fibroblast Growth Factor to a Soluble Receptor
tricarboxylic acid was also obtainable from Fischer
and for Mitogenesis in Whole Cells”, Molecular and
Scienti?c Co., Sigma Chemical Company, and Mallink
Cellular Biolog, Volume 12, (January 1992) pp. 25 rodt Chemical Co. (See Gonzalez, R. G. et al. “Frac
240-247; Klagsbrun, M. et al. “MINIREVIEW: A Dual
tionation and Structural Elucidation of the Active
Receptor System is Required for Basic Fibroblast
Components of Aurintricarboxylic Acid, a Potent In
Growth Factor Activity”, Cell, pp. 229-231; Risau, W.,
hibitor of Protein Nucleic Acid Interactions”, Bio
“Angiogenic Growth Factors”, Progress in Growth Fac
chimica et Biophysica Acta, Volume 562, (1979) pp.

Fibroblast Growth Factor Receptor Kinase”, Science,
Volume 259, (Mar. 26, 1993) pp. 1918-1921; Ornitz, D.
M. et a1. “Heparin is Required for Cell-free Binding of

tor Research, Volume 2, (1990) pp. 71-79; Bouck, N., 30 534-545).
“Tumor Angiogenesis: The Role of Oncogenes and
Heparin sodium USP (PM-20487, activity 171 U/mg)
Tumor Suppressor Genes”, Cancer Cells, Volume 2,
was a gift from Dr. Judah Folkman, Boston, Mass. The

Number 6, (June 1990) pp. 179-185).
A series of negatively charged aromatic compounds

steroids were obtained from Sigma Chemical Co., St.

ceptor Kinase”, Science, Volume 259, (Mar. 26, 1993)

45 Presence of Heparin or a Heparin Fragment”, Science

Louis, M0. or Steraloids, Inc., Wilton, NH. All other
which mimic many of the effects of heparin, including 35 chemicals were of reagent grade. Fertilized eggs (SPF
suramin and ATA, compete with FGF binding with
grade) were obtained from Sunrise Farms (Catskill,
heparin sulfate on the cell surface (Benezra, M. et al.,
NY).
“Reversal of Basic Fibroblast Growth Factor-mediated
The ability of suramin compounds to inhibit angio
Autocrine Cell Transformation by Aromatic Anionic
genesis was determined as previously described (Ga
Compounds”, Cancer Research, Volume 52, (Oct. 15, 40 gliardi, A. et al., “Inhibition of Angiogenesis by Sura
1992) pp. 5656-5662). The ability of solid tumors to
min,”, Cancer Research, Volume 52, (1992) pp.
grow to a clinically signi?cant size is dependent on
5073-5075), using a modi?cation of the chick chorioal
angiogenesis (Kan, M. et al. “An Essential Heparin
lantoic membrane (CAM) assay (Crum, R. et al., “A
binding Domain in the Fibroblast Growth Factor Re
New Class of Steroids Inhibits Angiogenesis in the
pp. 1918-1921. Stimulation of bFGF and the vasculo
tropin/endothelial cell growth factor is a critical event

(Washington,

in angiogenesis (Folkman, J. et al. “Anglogenesis Inhi
bition and Tumor Regression Caused by Heparin or a

embryos placed in petri dishes in a humidi?ed CO2
incubator (3% CO2/air) at 37° C. Each compound or

Heparin Fragment in the Presence of Cortisone”, Sci
ence, Volume 221, (Aug. 19, 1983) pp. 719-725).
Growth factors have been shown to be displaced
from their receptors by suramin (Benezra, M. et a1.

in methylcellulose (0.45%) and the solution (10 pl) was

DC),

Volume 230,

(1985)

pp.

1375-1378). The eggs were cracked on day 3 and the
combination of compounds to be tested were dissolved

air-dried on a Te?on-coated metal tray. The methylcel
lulose disk was implanted on the outer third of a day 6

“Reversal of Basic Fibroblast Growth Factor-mediated
CAM where capillaries were still growing. The disk
Autocrine Cell Transformation by Aromatic Anionic 55 alone and cortisol-Zl-phosphate (100 pg) plus heparin
Compounds”, Cancer Research, Volume 52, (Oct. 15,
(80 pg) were used as negative and positive controls,
1992) pp. 5656-5662), and it has been recently shown
respectively. The zone around the disk was examined 48
that suramin is a potent inhibitor of angiogenesis (Ga
hours after implantation and inhibition of anglogenesis
gliardi, A. et al., “Inhibition of Angiogenesis by Sura
was indicated by an avascular zone of 24 mm diameter

min”, Cancer Research, Volume 52, (Sep. 15, 1992) pp.

5073-5075).
ATA may mimic many of the actions of heparin with
out being mitogenic to endothelial cells (W eisz, P. B. et

around the disk. At least 20 embryos were measured for
each compound or combination of compounds. The
results were expressed as the percentage of embryos

which showed inhibition of angiogenesis.
The vessels of the CAM preparation grew rapidly
Key Principles—Science—Technology-Medicine, (eds. 65 until day 10, after which endothelial proliferation de
R. Steiner, P. B. Weisz & R. Langer), (1992) pp.
crease sharply (Ausprunk, D. R. et al., Developmental
107-117). Folkman et a1. (Folkman, J. et a1. “Angiogen
Biology, Volume 38, (1974) p. 237; Folkman, J. et al.
esis Inhibition and Tumor Regression Caused by Hepa
“Angiogenesis Inhibition and Tumor Regression

a1. “Anglogenesis and Heparin Mimics”, Angiogenesis:

5,434,185
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Caused by Heparin or a Heparin Fragment in the Pres
Aurintricarboxylic acid showed potent anti-angio
genic activity in a dose related manner. In the presence
ence of Cortisone”, Science, Volume 221, (1983) pp.
719-725). The effects of drug treatment on established
of heparin, the anti-angiogenic activity of aurintricar
vessels with low angiogenic activity were also deter
boxylic acid was decreased. Aurintricarboxylic acid
mined by implanting the compound or combination of 5 also potentiated the activity of the angiostatic steroids
compounds to be tested on day 13 and determining the
such as cortisol-Zl-phosphate, 17-a-hydroxyprogester

percentage of embryos showing inhibition of angiogen

one, tetrahydrocortexolone and tetrahydrocortisol.

esis on day 15 (late implants).

The above results indicate that ATA may effectively
replace heparin as an activator of angiostatic steroids

The effects of increasing amounts of ATA, aurin and
aurin plus heparin on the inhibition of angiogenesis are
shown in Table 1 and FIG. 1 below. ATA clearly inhib
ited anglogenesis when 4 pg were added to the disk
(35% inhibition), and the inhibition increased in a dose

(Table 2 below). We have previously shown (Gagliardi,
A. et al., “Inhibition of Angiogenesis by Suramin”,
Cancer Research, Volume 52, (1992) pp. 5073-5075) that
suramin can inhibit angiogenesis in the CAM prepara

tion. In addition, the anti-angiogenic activity of suramin
is antagonized by heparin. ATA, at concentrations 10

related manner to 91% when 32 pg of ATA were

added. On the other hand, aurin showed much lower

activity with 35% inhibition when 20 pg (molar equiva

fold lower than suramin, expressed a similar inhibitory
activity on angiogenesis.

lent to 32 pg of ATA) were added to the disk.

The angiostatic activity by ATA was reduced in the
The structures of ATA, suramin and heparin show
presence of 80 pg of heparin. This inhibition of the
important differences in chemical structure. The most
angiostatic activity of ATA was partially overcome by 20 notable difference being that the major polyanionic

increasing the concentration of ATA in the disk (Table
1, FIG. 1). On the other hand, the angiostatic activity

group in heparin and suramin is sulfonate, whereas

ied showed signi?cant inhibitory activity alone under

of 1,430 and ATA (although being a heterogenous mix
ture) had an estimated molecular weight of around
3,000—5,000 (Cushman, M. et al., “preparation and Anti
HIV activities of aurintricarboxylic acid fractions and
analogues: direct correlation of antiviral potency with

ATA contains carboxylate groups. Both suramin and
by aurin was not significantly changed in the presence
ATA contain aromatic rings lined via enzyme resistant
methylene groups, while heparin has a sugar backbone.
of heparin (Table 1, FIG. 1 below).
Table 2 below shows the percentage inhibition of 25 The molecular weights of these compounds are vastly
anglogenesis by several steroids either alone or in the
different. The heparin used in these studies had a molec
presence of heparin or ATA. None of the steroids stud
ular weight of 20,487, suramin had a molecular weight
the condition of the CAM assay. All the steroids exam

ined (cortisol-Zl-phosphate, l7-a-hydroxyprogester
one, tetrahydrocortexolone and tetrahydrocortisol)
exhibited signi?cant inhibition of angiogenesis in the
presence of 8 pg of ATA.

molecular weight”, J. Med. Chem., Volume 34, (1991)
Table 3 below shows the results for disks implanted
pp. 329-337). The presence of the carboxylic groups on
on day 13. ATA clearly exhibited angiostatic activity 35 ATA is considered to be important for angiostatic ac
with 85% inhibition at a concentration of 32 pg. Aurin
tivity because aurin, a chemically related compound
alone showed much less angiostatic activity with 10%
without the tricarboxylic residues, exhibits low anti
inhibition at an equivalent molar concentration. Only

angiogenic activity.

7

ATA and suramin exhibited angiostatic activity in both
The inhibitory effects of ATA and suramin in the
the early and late CAM preparation. Neither cortisol 40 13-day CAM preparation when FGF level in the CAM
2l-phosphate, tetrahydrocortisol, tetrahydrocortexo
?uid is very low suggest that these compounds may
lone nor l7a-hydroxyprogesterone in the presence of
affect blood vessels by mechanisms other than blocking
heparin nor tamoxifen, clomifene and ICI 182, 780 alone
bFGF action on endothelial cell growth.
showed angiostatic activity in the late CAM.
These novel ?ndings suggest that aurintricarboxylic
The results of these experiments clearly show that 45 acid provides the basis for important new therapeutic
ATA is a potent inhibitor of anglogenesis in the CAM.
approaches for diseases of neovascularization.
Furthermore, the inhibition of angiogenesis is dose de
Thus, the invention relates to a method comprising
pendent, increasing from 25% inhibition with 4 pg of
inhibiting angiogenesis by administering an effective
ATA to 91% inhibition at 32 pg. The angiostatic activ
amount of aurintricarboxylic acid, its analogues, deriva
ity of ATA is not dependent on the presence of heparin. 50 tives or salts. The invention comprises a method for the

treatment of angiogenesis-dependent diseases by admin
istering an effective amount of aurintricarboxylic acid,

Thus, ATA seems to be similar to, but more potent,

than suramin in its anti-angiogenic activity (Gagliardi,
A. et al., “Inhibition of Angiogenesis by Suramin”,
Cancer Research, Volume 52, (Sep. 15, 1992) pp.

5073-5075).
An additional ?nding from the above example is the
antagonism between ATA and heparin. The multiple
sulfate groups on heparin complex with molecules con
taining cationic centers, such as cationic dyes and pep

its analogues, derivatives or salts to a patient. Angiogen
esis dependent diseases include, but are not limited to
55

diabetic retinopathy, arthritis, tumor growth and metas
tasis and neovascular glaucoma. Treatments may in
clude an effective amount which comprises about 10

mg/kg/day of aurintricarboxylic acid.
In an alternative embodiment, the method for inhibit

tides/proteins with neighboring basic amino acid resi 60 ing angiogenesis includes administering an effective
dues (including FGF) (Weisz, P. B. et al., “Anglogene
amount of a composition comprising aurintricarboxylic
sis and Heparin Mimics”, Angiogenesis: Key Princi
acid, its analogues, derivatives or salts and asteroid

ples—Science—TechnoIogy-—Medicine, (eds. R. Steiner,
P. B. Weisz & R. Langer), (1992) pp. 107-117). In angio

composition to an animal. The steroid composition may
be selected from the group consisting of cortisol-21

genesis and endothelial cell growth promotion, heparin

phosphate, l7-a-hydroxyprogesterone, tetrahydrocor

like substances complex to bFGF, the cell surface and

texolone and tetrahydrocortisol or mixtures thereof.
The invention includes a pharmaceutical composition

to the extracellular matrix, thereby enhancing mitoge

nicity.

for the inhibition of angiogenesis comprising an anglo~

11
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genesis inhibiting amount of aurintricarboxylic acid and

The aurintricarboxylic acid compositions of the in

a steroid composition selected from the group consist

vention can be formulated into the compositions as
neutral or salt forms. Pharmaceutically acceptable non

ing of cortisol-Zl-phosphate, l7-a-hydroxyprogester
one, tetrahydrocortexolone and tetrahydrocortisol.
Compounds of the present invention have anti‘angio
genic properties in animals. Compounds of the present

toxic salts include the acid addition salts, for example,
hydrochloric or phosphoric acids or such organic acids
as ascetic, oxalic, tartaric, mandelic, etc. Salts formed
with free carboxyl groups may be derived from inor

invention and compositions which are shown to have

physiological effects of inhibiting angiogenesis ?nd use

ganic bases such as, for example, sodium, potassium,

in numerous therapeutical applications, such as the

ammonium, calcium or ferric hydroxides. Tissue cul
ture experiments show that ATA binds basic ?broblast
growth factor at pH 6.5-7.5. (Benezra, M. et al., “Re
versal of basic ?broblast growth-mediated autocrine

treatment of angiogenesis~dependent diseases, including
diabetic retinopathy, arthritis, tumor growth and metas
tasis and neovascular glaucoma.

Therapeutic compositions comprise an effective
amount of the compounds of the invention including
non-toxic addition salts. Such compositions can also be 15

cell transformation by aromatic anionic compounds”,
Cancer Research, Volume 52, (1992) pp. 5656-5662.
Thus it is preferred that pharmaceutical compositions of

provided together with physiologically tolerable liquid,

the invention have a pH of about 6.5—7.5.

gel or solid diluents, adjuvants and excipients.

TABLE 1

These compositions can be administered to animals
for veterinary use, such as with domestic animals and

Percentage of inhibition of angiogenesis for

clinical use in humans in a manner similar to other thera 20

different amounts of Aurintricarboxylic acid (ATA) and Aurin
alone and in combination with heparin. The number of

peutic agents. In general, the dosage required for thera

embryos showing inhibition/total embryos evaluated (+/total)

peutic efficacy will range from about 1 pg to 300
mg/kg, preferably 10 pg to 30 mg/kg of the host body
weight, and more preferably about 6.7 mg/kg or 10.0

and the percentage showing inhibition (% of inhibition) are

mg/kg of host body weight of aurintricarboxylic acid.

shown.

25

Disk only
2 pg ATA

Alternatively, dosages within these ranges can be ad
ministered by constant infusion over an extended period

of time, usually exceeding 24 hours, until the desired
therapeutic bene?ts have been obtained. The chemical
structure suggests that this compound will be ef?ciently
absorbed from the gut. One may also deliver this mate

rial directly into the eye using implants of via an implant
in or on the skin.

Typically such compositions are prepared as injecta 35

bles, either as liquid solutions or suspensions; solid
forms suitable for solution in, or suspension in, liquid

prior to injection may also be prepared. The prepara
tion may also be emulsi?ed. The active ingredient is
often mixed with diluents or excipients which are physi
ologically tolerable and compatible with the active
ingredient. Suitable diluents and excipients are, for ex
ample, water, saline, dextrose, glycerol, or the like, and
combinations thereof. In addition, if desired, the com
positions may contain minor amounts of auxiliary sub

EMBRYOS
(+/total)
0/ 25
3/22

COMPOUND

45

stances such as wetting or emulsifying agents, stabiliz

% of
Inhibition

4 pg ATA
8 pg ATA
16 pg ATA
32 pg ATA
64 pg ATA
1.25 pg Aurin

5/20
8/21
12/20
20/ 22
23/23
0/20

2.50 pg Aurin
5.00 pg Aurin
10.00 pg Aurin
20.00 pg Aurin
pg ATA
2 + 80 pg heparin
4 + 80 pg heparin
8 + 80 pg heparin
16 + 80 pg heparin
32 + 80 pg heparin
64 + 80 pg heparin
pg Aurin
1.25 + 80 pg heparin
2.50 + 80 pg heparin
5.00 + 80 pg heparin
10.00 + 80 pg heparin
20.00 + 80 pg heparin

0/24
1/23
2/21
10/29

0
14
25
38
60
91
100
0
0
4
10
35

0/22
0/21
3/20
8/20
12/20
17/21

0
0
15
40
60
81

0/22
0/20
0/22
1/20
4/20

0
0
0
5
20

ing agents, or pH buffering agents, and the like.
The compositions are conventionally administered by
injection, either subcutaneously or intravenously. Addi

TABLE 2

tional formulations which are suitable for other modes

Percentage of Inhibition of Angiogenesis for Angiostatic

of administration include, suppositories, intranasal aero
sol, and in some cases, oral formulations. For supposito

increasing amounts of aurintricarboxylic acid (ATA). The number

Steroids alone or in the presence of 100 pg of heparin or

of embryos showing inhibition/total embryos evaluated (+/total)

ries, traditional binders and excipients may include, for

example, polyalkylene glycols or triglycerides: such
suppositories may be formed from mixtures containing

and the percentage showing inhibition (% of inhibition) are shown.
EMBRYOS
% of

55

the active ingredient in the range of 0.5 to 10%, prefera
bly 1-2%. Oral formulations include such normally

COMPOUND
100 pg cortisol-Zl-phosphate only
+2 pg ATA

-

employed excipients as, for example, pharmaceutical
grades of mannitol, lactose, starch, magnesium stearate,
sodium saccharine, cellulose, magnesium carbonate,

+4
+8
+16
+32

and other conventional additives. These compositions

+80 pg heparin
100 pg l7a-hydroxyprogesterone

take the form of solutions, suspensions, tablets, pills,
capsules, sustained release formulations or powders and
contain 10% to 90% of the active ingredient, preferably
25% to 70%. These oral formulations are designed to 65

protect the activity of the'aurintricarboxylic acid com
position or its derivative or analogue until it can be

absorbed.

pg
pg
pg
pg

ATA
ATA
ATA
ATA

(+/total)
8/29

Inhibition
26

8/22

36

10/20
1.8/21
20/21
23/23

50
86
95
100

27/41
0/54

66
0

11/23
16/20
22/23
26/58

48
69
95
45

0/53
8/22

0
36
59

only
+2 pg ATA
+4 pg ATA
+8 pg ATA

+80
100
+2
+4

pg heparin
pg tetrahydroeortisol only
pg ATA
pg ATA

13/22
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TABLE 2-continued

TABLE 3'contmued

Percentage of Inhibition of Angiogenesis for Angiostatic

Percentage of Inhibition of Angiogenesis for Several
Compounds Implanted on the Late CAM (Day 13) and Early

-

-

-

Stero1ds alone or in the presence of 100 pg of heparin or

5

CAM (Day 6). The number of embryos showing inhibition/total

embryos evaluated (+/t°ta1) and the percentage showing

increasing amounts of aurintricarboxylic acid (ATA). The number
of embryos showing inhibition/total embryos evaluated (+/total)

inhibition (% of inhibition) are shown.
LATE CAM
EARLY CAM

and the percerlage showing inhibition (% of inhibition) are shown.
% of

10 COMPOUND

(+/tota1)

Inhibition

(100 as) +

22/25

88

COMPOUND

133$‘

EMBRYOS

I315;

EMBRYOS

tion

(+/tota.l)

tion

(+/total)

0

(0/18)

59

(13/22) .

0

(0/22)

61

(25/40)

1-

EMBRYOS

_

heparin (100 pg)
+8 pg ATA
_

+80 “g hepan“
100 pg medroxyprogesterone acetate

17/38

45

0/59

0

Clomiphene
(100 111;)

Tamoxifen
15 (100 pg)

(m1

1c1 182,780
y

Y

9/21

43

+4 "g ATA
+3 pg ATA

13/23
14/20

56
70

0/24

0

+

h

'

“g epam

80 pg heparin only

0

(0/19)

20

(24/30)

74
85
10

(26/35)
(17/20)
(2/20)

58
91
35

(15/26)
(20/22)
(10/29)

(100 Mg)

+2 pg ATA

80

1

Suramin (100 pg)
ATA (32 pg)
Aurin (10 pg)
20

.

.

.

.

Although the foregoing invention has been descnbed
in some detail by way of illustration and example for

0/23

purposes of clarity and understanding, it will be obvious
that certain changes and modi?cations may be practiced
TABLE 3
Percentage of Inhibition of Angiogenesis for Several
Compounds Implanted on the Late CAM (Day 13) and Early

CAM (Day 6) The number °f embry“ sh°wing inhibi?W/mal
embryos evaluated (+/total) and the percentage showing
inhibition (% ofinhjbition) are Shown

LATE CAM

% of

COMPOUND

EARLY CAM

25 within the scope of the appended claims.
We claim:
1. A method for inhibiting angiogenesis in an animal
comprising administering an effective amount to inhibit
anglogenesis of aurintricarboxylic acid, its analogues, 01'
30 salts to said animal.
2. A method according to claim 1, wherein said ani
mal is a mammal or bird.
3. A method according to claim 1, wherein said effec

% 0f

tive amount comprises about 10 mg/kg body weight of

Inhibi~

EMBRYOS

Inhibi-

EMBRYOS

tion

(+/total)

tion

(+ howl)

Disk only

0

(0/25)

0

(0/23)

cortisol-2l-PO4

5

(V18)

66

(27/41)

35 the host of aurintricarboxylic acid.

_4. A method according to cla1m 1, wherein sald aurm

tricarboxyllc acid has a molecular weight of about 3000
to 5000‘
*

4O

45

5O

55

60

*

*

*

*

